Coya Therapeutics FY2024 net loss $14.9M; cash $38.3M; pipeline updates for ALS and FTD trials

Coya Therapeutics, Inc.

Net loss $14.9M in 2024 vs $8.0M in 2023; R&D expenses $11.9M (up from $5.5M).
Cash and equivalents $38.3M as of Dec 31, 2024; raised $10M private placement and $5M from ADDF.
Received $3.85M from Dr. Reddy's for COYA-302 ALS Phase 2; eligible for additional $8.4M milestone.
Plan to submit nonclinical data to FDA in Q2 2025 for COYA-302 ALS Phase 2b trial initiation.
Expect to file IND for COYA-302 Phase 2b in FTD in 2H 2025; top-line data from investigator trial also in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.